Tracers / [89Zr]vMET1-Fc
[89Zr]vMET1-Fc
Also written as [Zr-89]Zr-vMET1-Fc
- Radionuclide
- Zr-89 t½ 4704 min
- Modality
- Therapy
- Production route
- —
- Stage
- preclinical study
- Syntheses indexed
- 1
What it is
- Compound class
- Shark-derived single-domain VNAR antibody fused to human Fc domain (VNAR-Fc theranostic construct)
- Target / mechanism
- Targets MET receptor tyrosine kinase, internalized by MET-positive cells PMID 41676672
- Clinical application
- PET/CT imaging of MET-altered NSCLC as part of a theranostic pair with [177Lu]Lu-vMET1-Fc for radiotherapy PMID 41676672
- Theranostic pair
- <a href="/tracers/lu177-vmet1fc/">lu177-vmet1fc</a>
Regulatory status
- FDA
- —
- EMA (centralised)
- —
- Other approvals
- —
- Brand names
- —
Clinical use
- Typical injected activity
- —
- Uptake time
- —
Reported in the literature. Not a dosing recommendation.
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| — | — | — | — | — | vMET1-Fc | 41676672 2026 bioRxiv |
Need this precursor?We can point you to suppliers for [89Zr]vMET1-Fc, or handle the enquiry for you.
Get in touchNotes
Added at stage 22: promoted from 'Reported once' (single-article, no diagnostic pair at discovery) because a full-text synthesis with extracted data exists in parsed-therapy.xlsx -- PMID(s): 41676672. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Stage set/updated at stage 23 from PMID 41676672: 'High tumor uptake with low background was observed in MET-positive NSCLC xenografts administered [89Zr]Zr-vMET1-Fc.'.